Overview

A Study Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer.

Status:
Active, not recruiting

Trial end date:
2022-07-20

Target enrollment:

Participant gender:

Summary

An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of Tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced Squamous NSCLC. 45 sites will be involved in China, 342 participants will be enrolled.

Phase:

Phase 3

Details

Lead Sponsor:

BeiGene

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel